Calibr-Skaggs Institute for Innovative Medicines
Scripps Research’s drug discovery engine powers life-changing therapies.
The Calibr-Skaggs Institute for Innovative Medicines is a nonprofit drug discovery engine built to accelerate the development of transformative medicines. As the translational research arm of Scripps Research, Calibr-Skaggs is akin to a biotech embedded within the nonprofit research ecosystem—a unique model among academic institutes. The Calibr-Skaggs team shrinks the gap between scientific discovery and clinical application to bring the boldest ideas in biomedicine to those who need them most.
Disease Areas
At Calibr-Skaggs, we’re here because we want to positively impact patients’ lives. We’re committed to discovering and developing new medicines across a broad range of conditions, including aging-related, neurological, inflammatory and metabolic diseases, as well as cancer and global health. We combine cutting-edge science and robust drug discovery methodology to advance these promising treatments toward patients, faster.
Platforms and Technologies
Our state-of-the-art technology platforms, anchored by medicinal chemistry, form the backbone of our fully integrated drug discovery and development engine. This includes our open-access drug repurposing library, ReFRAME; proprietary long-acting and oral platforms; DNA-encoded libraries; cell-based screens for target identification; protein and antibody engineering platforms; and much more.
Pipeline
Calibr-Skaggs pursues novel approaches to not just treat, but cure. The institute’s diverse portfolio reflects a daring mission of tackling global health challenges, efficiently and at scale. Several therapies are in the clinic, and many more are progressing rapidly behind them, fueled by integrated platforms and translational infrastructure.
People
The Calibr-Skaggs team is fluent in both foundational research and therapeutic development, allowing us to merge groundbreaking science with experienced drug development. This multi-disciplinary group fuels a more agile, effective and patient-centered approach to drug invention.
